论文信息 - Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium - 字舞流文

Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium

Key Points • Currently, patients receive a single dose of tisagenlecleucel across a wide dose range.• Clinicians could choose to give a higher dose of tisagenlecleucel upfront, within the approved dose range, to optimize response.

Snehit Prabhu | M. Hermiston | C. Mackall | K. Curran | T. Laetsch | M. Verneris | H. Stefanski | M. Qayed | C. Baggott | J. Talano | J. Rossoff | P. Satwani | Liora M. Schultz | C. Rabik | S. Margossian | A. Keating | C. Phillips | Christa Krupski | A. Goksenin | N. Karras | E. Egeler | Amy Moskop | G. D. Myers | H. Pacenta | Vanessa A. Fabrizio | Vasant Chinnabhandar | S. Mavroukakis | R. Wilcox | Patrick A. Brown | Anne A Eaton | Holly L. Pacenta

[1] N. Kröger,et al. Axicabtagene ciloleucel in vivo expansion and treatment outcome in aggressive B-cell lymphoma in a real-world setting. , 2021, Blood advances.

[2] A. Logan,et al. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. , 2021, Blood.

[3] Matthew J. Frigault,et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. , 2020, Blood advances.

[4] S. Grupp,et al. Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia , 2018, Clinical Cancer Research.

[5] S. Rives,et al. Considerations for tisagenlecleucel dosing rationale. , 2018 .

[6] K. Davis,et al. Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia , 2018, The New England journal of medicine.

[7] Pamela A Shaw,et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[8] S. Rosenberg,et al. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. , 2010, Blood.

[9] W. Wilson,et al. Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor , 2009, Journal of immunotherapy.

[10] D. Campana,et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[11] K. Hornik,et al. A Lego System for Conditional Inference , 2006 .

[12] F. Yates. The analysis of contingency tables with groupings based on quantitative characters. , 1948, Biometrika.

[13] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .